AB0518 EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS E...
AB0518 EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): RESULT OF THE LILAC PHASE 2 STUDY
About this item
Full title
Author / Creator
Furie, R. , Werth, V. , Milliman, E. , Ferber, K. , Casey, F. , Brown, R. , Raitcheva, D. , Zoghbi, J. , Graham, D. , Kong, G. , Lahoud, Y. , Franchimont, N. and Barbey, C.
Publisher
Kidlington: Elsevier B.V
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier B.V
Subjects
More information
Scope and Contents
Contents
Litifilimab (BIIB059) is a humanised IgG1 monoclonal antibody targeting BDCA2, a receptor predominantly expressed on plasmacytoid dendritic cells, that negatively regulates production of Type I IFN and proinflammatory chemokines and cytokines [1,2]. Both Part A (SLE) and Part B (CLE) of the randomised, placebo-controlled Phase 2 LILAC study of liti...
Alternative Titles
Full title
AB0518 EFFECT OF LITIFILIMAB ON TYPE I INTERFERON (IFN) BIOMARKERS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) OR CUTANEOUS LUPUS ERYTHEMATOSUS (CLE): RESULT OF THE LILAC PHASE 2 STUDY
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2820819678
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2820819678
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.2704
